These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 14986243)
1. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Collin S; Davidson R; Ritmeijer K; Keus K; Melaku Y; Kipngetich S; Davies C Clin Infect Dis; 2004 Mar; 38(5):612-9. PubMed ID: 14986243 [TBL] [Abstract][Full Text] [Related]
2. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Melaku Y; Collin SM; Keus K; Gatluak F; Ritmeijer K; Davidson RN Am J Trop Med Hyg; 2007 Jul; 77(1):89-94. PubMed ID: 17620635 [TBL] [Abstract][Full Text] [Related]
3. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan. Atia AM; Mumina A; Tayler-Smith K; Boulle P; Alcoba G; Elhag MS; Alnour M; Shah S; Chappuis F; van Griensven J; Zachariah R Trop Med Int Health; 2015 Dec; 20(12):1674-84. PubMed ID: 26427033 [TBL] [Abstract][Full Text] [Related]
4. Unseen Kala-azar deaths in south Sudan (1999-2002). Collin SM; Coleman PG; Ritmeijer K; Davidson RN Trop Med Int Health; 2006 Apr; 11(4):509-12. PubMed ID: 16553934 [TBL] [Abstract][Full Text] [Related]
5. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis. Zijlstra EE; Khalil EA; Kager PA; El-Hassan AM Br J Dermatol; 2000 Jul; 143(1):136-43. PubMed ID: 10886148 [TBL] [Abstract][Full Text] [Related]
6. Utility of lymph node aspiration in the diagnosis of visceral leishmaniasis in Sudan. Babiker ZO; Davidson R; Mazinda C; Kipngetich S; Ritmeijer K Am J Trop Med Hyg; 2007 Apr; 76(4):689-93. PubMed ID: 17426171 [TBL] [Abstract][Full Text] [Related]
7. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis. Singh R; Kumar D; Ramesh V; Negi NS; Singh S; Salotra P J Infect Dis; 2006 Aug; 194(3):302-6. PubMed ID: 16826477 [TBL] [Abstract][Full Text] [Related]
8. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Musa AM; Khalil EA; Mahgoub FA; Elgawi SH; Modabber F; Elkadaru AE; Aboud MH; Noazin S; Ghalib HW; El-Hassan AM; Trans R Soc Trop Med Hyg; 2008 Jan; 102(1):58-63. PubMed ID: 17963805 [TBL] [Abstract][Full Text] [Related]
9. Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Seaman J; Mercer AJ; Sondorp HE; Herwaldt BL Ann Intern Med; 1996 Apr; 124(7):664-72. PubMed ID: 8607595 [TBL] [Abstract][Full Text] [Related]
10. A thirty day course of sodium stibogluconate for treatment of Kala-azar in Nepal. Karki P; Koirala S; Parija SC; Hansdak SG; Das ML Southeast Asian J Trop Med Public Health; 1998 Mar; 29(1):154-8. PubMed ID: 9740292 [TBL] [Abstract][Full Text] [Related]
11. Seroepidemiological study on kala-azar in Baringo District, Kenya. Jahn A; Lelmett JM; Diesfeld HJ J Trop Med Hyg; 1986 Apr; 89(2):91-104. PubMed ID: 3021967 [TBL] [Abstract][Full Text] [Related]
12. Elevated levels of interferon-gamma, interleukin-10, and interleukin-6 during active disease in Indian kala azar. Ansari NA; Saluja S; Salotra P Clin Immunol; 2006 Jun; 119(3):339-45. PubMed ID: 16540374 [TBL] [Abstract][Full Text] [Related]
13. Observations on the effect of verapamil with sodium stibogluconate in kala azar. Thakur CP; Kumar M Trop Geogr Med; 1992 Jan; 44(1-2):15-8. PubMed ID: 1323160 [TBL] [Abstract][Full Text] [Related]
14. Post kala-azar dermal leishmaniasis: the Kenyan experience. Muigai R; Gachihi GS; Oster CN; Were JB; Nyakundi PM; Chunge CN; Kirigi G; Rashid JR East Afr Med J; 1991 Oct; 68(10):801-6. PubMed ID: 1667521 [TBL] [Abstract][Full Text] [Related]
15. Endemic kala-azar in eastern Sudan: post-kala-azar dermal leishmaniasis. Zijlstra EE; el-Hassan AM; Ismael A Am J Trop Med Hyg; 1995 Apr; 52(4):299-305. PubMed ID: 7741164 [TBL] [Abstract][Full Text] [Related]
16. Post kala azar dermal leishmaniasis in Sudan. Kordofani YM; Nour YT; El-Hassan AM; Shalayel MH East Mediterr Health J; 2001 Nov; 7(6):1061-4. PubMed ID: 15332749 [TBL] [Abstract][Full Text] [Related]
17. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Moore E; O'Flaherty D; Heuvelmans H; Seaman J; Veeken H; de Wit S; Davidson RN Bull World Health Organ; 2001; 79(5):388-93. PubMed ID: 11417033 [TBL] [Abstract][Full Text] [Related]
18. Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis). Thakur CP Trans R Soc Trop Med Hyg; 1984; 78(3):391-8. PubMed ID: 6087515 [TBL] [Abstract][Full Text] [Related]
19. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. Mueller M; Balasegaram M; Koummuki Y; Ritmeijer K; Santana MR; Davidson R J Antimicrob Chemother; 2006 Oct; 58(4):811-5. PubMed ID: 16916865 [TBL] [Abstract][Full Text] [Related]
20. Deaths in visceral leishmaniasis (Kala-azar) during treatment. Ahasan HA; Chowdhury MA; Azhar MA; Rafiqueuddin AK; Azad KA Med J Malaysia; 1996 Mar; 51(1):29-32. PubMed ID: 10967976 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]